MicroRNA Biomarkers for Coronary Artery Disease?
MicroRNA (miRNA, miR) measurements in patients with coronary heart disease are hampered by the confounding effects of medication commonly used in cardiovascular patients such as statins, antiplatelet drugs, and heparin administration. Statins reduce the circulating levels of liver-derived miR-122. Antiplatelet medication attenuates the release of platelet-derived miRNAs. Heparin inhibits the polymerase chain reactions, in particular the amplification of the exogenous Caenorhabditis elegans spike-in control, thereby resulting in an artefactual rise of endogenous miRNAs. As these limitations have not been previously recognised, a reevaluation of the current miRNA literature, in particular of case-control studies in patients with cardiovascular disease or coronary interventions, is required.
King's British Heart Foundation Centre, King's College London, 125 Coldharbour Lane, London, SE59NU, UK.
Dorothee
D
Kaudewitz
King's British Heart Foundation Centre, King's College London, 125 Coldharbour Lane, London, SE59NU, UK.
Anna
A
Zampetaki
King's British Heart Foundation Centre, King's College London, 125 Coldharbour Lane, London, SE59NU, UK. manuel.mayr@kcl.ac.uk.
Manuel
http://orcid.org/0000-0002-0597-829X
M
Mayr
D000818:Animals; D015415:Biomarkers / Q000032:analysis; D003324:Coronary Artery Disease / Q000188:drug therapy / Q000235:genetics*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D035683:MicroRNAs / Q000235:genetics*; D009203:Myocardial Infarction / Q000235:genetics; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use
D015415:Biomarkers; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D035683:MicroRNAs; D010975:Platelet Aggregation Inhibitors
Biomarker; Cardiovascular; Coronary heart disease; MicroRNA; Myocardial infarction